



Cite this: *RSC Adv.*, 2018, 8, 40778

## NMR insights on nano silver post-surgical treatment of superficial caseous lymphadenitis in small ruminants†

Danijela Stanic, \*<sup>a</sup> Natália L. Fregonesi,<sup>a</sup> Caio H. N. Barros,<sup>a</sup> João G. M. Pontes,<sup>a</sup> Stephanie Fulaz,<sup>a</sup> Ulisses J. Menezes,<sup>b</sup> Jorge L. Nicoleti,<sup>b</sup> Thiago L. P. Castro,<sup>c</sup> Núbia Seyffert,<sup>d</sup> Vasco Azevedo,<sup>c</sup> Nelson Durán,<sup>ef</sup> Ricardo W. Portela<sup>b</sup> and Ljubica Tasic \*<sup>ae</sup>

Caseous lymphadenitis (CL), caused by a pathogen of the second class of biosafety – *Corynebacterium pseudotuberculosis*, is a chronic and severe infectious disease that affects small ruminants and requires long, ineffective treatment which generally leads to animal sacrifice so as to stop the disease spreading. The infected animals suffer the excision of affected superficial lymph nodes and post-surgical treatment with iodine (10% solution in ethanol) and, sometimes, prolonged antibiotic use, but only if the sick animals are of great importance to breeding. Herein, we propose a cheap and easy to apply treatment of CL with excellent results using biogenic silver nanoparticles (AgNP) based technology. AgNP antibacterial properties were investigated *in vitro* against *Corynebacterium pseudotuberculosis* cells and *in vivo* on small ruminants with CL. Treatment of surgical wounds resulting from the excision of superficial CL lesions with a AgNP-based cream was compared to the standard post-surgical treatment method by iodine. Also, the effects of AgNP-based cream treatment were evaluated and compared with the effects of the iodine CL treatment by serum NMR-based metabolomics. Serum samples were collected from 29 animals, 9 sheep and 20 goats, during the treatments and analyzed. All animals showed stable serum metabolomes when iodine or AgNP-based cream effects were compared. The AgNP-based cream treatment showed excellent results, especially in accelerating the healing of wounds, which occurred two to three times faster in comparison with the iodine treatment. AgNP-based cream treatment also prevented CL reappearance and did not cause any side effects on animals. This is the first report on very effective post-surgical treatment of superficial CL in small ruminants based on biogenic silver nanoparticles, which might open up the possibility for a safe veterinary application of AgNP-based cream.

Received 4th October 2018  
Accepted 24th November 2018

DOI: 10.1039/c8ra08218a

[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

## Introduction

*Corynebacterium pseudotuberculosis* (*C. pseudotuberculosis*) is a Gram positive,<sup>1,2</sup> non-encapsulated, facultative and intracellular bacterium, which is the etiological agent of caseous

lymphadenitis (CL) in small ruminants (biovar *ovis*) and ulcerative lymphadenitis in equines (biovar *equi*).<sup>3</sup> This disease provokes great economic losses worldwide and affects wool, meat and milk production.<sup>3,4</sup> Many efforts have been made toward a better understanding of the *C. pseudotuberculosis* pathogenicity through genomics, proteomics and metabolomics,<sup>1,5,6</sup> but the host-microorganism interaction mechanisms in CL are still not understood. Also, *C. pseudotuberculosis* is not an easy target for antibiotics. The encapsulated lesions in CL do not allow an easy penetration of drugs, thus, treatment is long and not effective in most cases. There are many efforts towards finding better CL treatments, for example, *in vitro* evaluation of antimicrobial susceptibility of *C. pseudotuberculosis* using a variety of antibiotics.<sup>7,8</sup> Recently, silver and gold nanoparticles were tested<sup>9–11</sup> and their antimicrobial activities against the *C. pseudotuberculosis*<sup>11</sup> were reported. The current treatment of the CL depends on excision of lesions in superficial lymph nodes and the use

<sup>a</sup>Laboratório de Química Biológica, Departamento de Química Orgânica, Instituto de Química, Universidade Estadual de Campinas, Campinas, SP, Brazil. E-mail: [ljubica@iqm.unicamp.br](mailto:ljubica@iqm.unicamp.br)

<sup>b</sup>Laboratório de Imunologia e Biologia Molecular, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, BA, Brazil

<sup>c</sup>Departamento de Biologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

<sup>d</sup>Laboratório de Bacteriologia e Saúde, Instituto de Biologia, Universidade Federal da Bahia, Brazil

<sup>e</sup>NanoBioss – Institute of Chemistry, University of Campinas, Campinas, SP, Brazil

<sup>f</sup>UFABC, São Paulo, SP, Brazil

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c8ra08218a



of an iodine solution (10% in 70% of ethanol) for sterilization of surgical wounds, but iodine showed to be histotoxic and prolonged the wound healing process.<sup>12</sup>

Silver antimicrobial activity is antique<sup>10</sup> and silver(I) has been used for treatment of wounds and ulcers from 18<sup>th</sup> century.<sup>13</sup> The bactericidal effects of silver(I) had been described for many microorganisms, such as *Escherichia coli*,<sup>14</sup> *Staphylococcus aureus*,<sup>15,16</sup> *Candida albicans*, *Xanthomonas axonopodis* pv. *citri*<sup>17</sup> and others.<sup>18–20</sup> However, the action mechanism of silver(I) is not fully understood.<sup>21</sup> In addition, silver nanoparticles (AgNPs)<sup>22–27</sup> have a pronounced antibiotic activity and can decrease the inflammatory cascade and tissue proliferation. The last two processes count on fibroblast cells activity that leads to a faster wound healing and formation of more organized collagen fibres without creating scars.<sup>23</sup>

Therefore, we hypothesized that AgNP application might assist in CL treatment in a practical and a cheap way if bio-based particles could be applied, as to avoid the use of chemically synthesized AgNPs, which might have undesired effects, even in regard of environmental issues. But before recommended for use for animal and/or human treatment, the AgNP toxicity needs to be tested.

The current study aimed to formulate the biogenic AgNP-based skin-friendly cream for dermal use and apply it on post-surgery wounds of CL-suffering animals. Also, the effectiveness of AgNP-based cream was compared with the CL iodine treatment. Eventual toxic effects of AgNPs on treated animals were monitored through biochemical tests and serum metabolomics by NMR.<sup>6,28–37</sup> Two types of AgNPs were tested, biogenic *Fusarium oxysporum* ones and bio-based AgNPs from *Citrus sinensis* peel extracts.<sup>18,38</sup>

## Materials and methods

### Biogenic silver nanoparticles (AgNP) syntheses

The synthesis of AgNPs from *Fusarium oxysporum* was done based on the procedure described by Ballottin *et al.* (2017).<sup>17</sup> Briefly, 10 g of fungal filtrate (*Fusarium oxysporum*) was mixed with a silver nitrate solution (1 mmol L<sup>−1</sup>), which formed nano silver in 72 h in the dark.<sup>17</sup>

On the other hand, the synthesis of AgNPs with orange peel extract was performed as described by Barros *et al.* (2018).<sup>38</sup> Briefly, an orange peel extract was made by mixing 50 g of chopped peel with water and after heating it up to the boiling point. Then, using filtration and a 0.22 μm pore membrane, the orange peel extract was obtained and added to a silver nitrate solution (1 mmol L<sup>−1</sup>) and kept in the dark for 48 h.<sup>38</sup>

These nano silver particles<sup>17,38</sup> were characterized and showed the following physical–chemical properties: (a) *F. oxysporum* AgNPs had sizes of 28.0 ± 13.1 nm, showed polydispersity of 0.231, zeta potential of −31.7 ± 2.8 mV, and were spherical in form; (b) orange peel AgNPs had sizes of 48.1 ± 20.5 nm and polydispersity of 0.312, zeta potential of −19.0 ± 0.4 mV, also, were spherical.

### *C. pseudotuberculosis* cells and AgNP activities

The *C. pseudotuberculosis* strain 1002 was provided by Laboratório de Genética Celular e Molecular (LGCM, UFMG, Belo Horizonte, Brazil) and maintained in glycerol at −80 °C, until cultivation in Brain Heart Infusion (BHI) broth at 37 °C for 40 h. *C. pseudotuberculosis* was grown in the culture medium, centrifuged and transferred to a NaCl solution (0.9%) with dilution monitored by turbidity at 600 nm (0.1). Then, bacteria were pipetted in sterile 96-well plates.

A volume of 100 μL bacterial culture and 100 μL of sterile medium culture was pipetted in the first row of the plate (Positive Control) and in row 2, 100 μL of AgNP suspension and 100 μL of sterile culture medium were added (Negative Control). In row 3, 200 μL of the AgNP 268 μg mL<sup>−1</sup> were added and from rows 4 to 12, the concentrations of AgNPs were adjusted to 28, 26, 24, 22, 20, 18, 16, 14, 12 μg mL<sup>−1</sup> using sterile culture medium. In the case of orange extract based AgNPs, the stock suspension of 54 μg mL<sup>−1</sup> was also diluted through rows 4 to 12, reaching concentrations of 35, 30, 25, 20, 15, 5, 2 and 1 μg mL<sup>−1</sup>. 50 μL of bacterial culture (turbidity at 600 nm was 0.1) were added to the wells of rows 4 through 12. The plates were incubated at 37 °C for 48 h, and bacterial growth was monitored by visual detection of turbidity.<sup>39</sup>

### Scanning electron microscopy analyses

Bacterial suspensions in conditions mimicking the MIC assays at the MIC and one half of MIC concentration were deposited in 0.45 μm pore sized, 25 mm PTFE membrane (Millipore®), fixed with 2.5% glutaraldehyde solution in sodium phosphate buffer at pH 7.2 and washed twice with PBS (pH = 7.4) buffer. The membrane was soaked with osmium tetroxide 1.0% for 1 h and washed twice with distilled water. The dehydration process consisted in immersing the membrane in ethanol 30% for 20 min, 50% for 20 min; 70% for 16 h; 90% for 20 min and three times in ethanol p.a. for 20 min. The drying was performed in a Critical Point Dryer (CPD) (Balzers® CPD-0.30), the sputtering with gold by Sputter Coater SCD-050 and SEM analyses in a Jeol® JSM 5800LV microscope.

### AgNP-based cream formulation

The cream formulations with AgNPs were made with a natural oily base and nanoparticles obtained by two described methods, which were incorporated after preparing the base. The cream in the water-in-oil base was prepared by heating the natural

Table 1 Composition of AgNP-based cream

Phase	Trade name	INCI name	w/w%	Supplier
A	Lanolin	Lanolin	20.0	Fagron
	Cera alba	Cera alba	9.0	Fagron
	Vaselinum solidum	Petroleum	31.0	Fagron
	Vaselinum liquidum	Paraffinum liquidum	10.0	Fagron
	Cetostearyl alcohol	Cetostearyl alcohol	8.0	Fagron
B	Cholesterol	Cholesterol	2.0	Fagron
	AgNPs	AgNPs	20.0	Unicamp



ingredients (Table 1, formulation described in patent – BR102017014836022) at 60 °C under stirring, followed by the addition of the AgNP colloid solutions at room temperature, adjusted to the MIC concentration.

A grey coloured cream with oily consistency, easy to apply and with the property to leave a greasy film on the skin was obtained.

### Nuclear magnetic resonance spectroscopy analyses

Acquisition of the all 1D and 2D ( $^1\text{H}$  and  $^{13}\text{C}$ ) Nuclear Magnetic Resonance – NMR spectra were done on a Bruker *Avance III* 600 MHz spectrometer, utilizing TBI – Triple Resonance Broadband Inverse probe at 25 °C.

### NMR sample preparation for *C. pseudotuberculosis* analysis – *in vitro*

For this NMR analysis and subsequent metabolomics, 3 distinct groups were studied. In all groups, *C. pseudotuberculosis* was grown in 10 mL of BHI media. For group 1, the bacterial cultures were grown for 24 h at 200 rpm and 32 °C. To the culture media of groups 2 and 3, 10 mL of ampicillin (0.25  $\mu\text{g mL}^{-1}$ ) and 10 mL of AgNPs (20  $\mu\text{g mL}^{-1}$ ) were added, respectively, after 16 h of agitation. Then, the cultures were grown for another 8 h, reaching turbidity at 600 nm of 0.8.

By adding ethanol, in the ratio 1 : 1 (v/v) to the bacterial cultures, the growth of *C. pseudotuberculosis* was quenched. Then, the suspensions were centrifuged for 10 min at  $7000 \times g$  at 4 °C, and the cells were suspended in 30 mL of ice-cold PBS (20 mmol  $\text{L}^{-1}$ , pH = 7.2, 0 °C); this step was repeated twice. The cells were lysed by ultrasonication for 10 s (Ultrasonique). The obtained biological material was centrifuged at  $17\,000 \times g$  during 2 min, then the supernatant was kept, cell residues were washed, and the supernatants were combined and lyophilized.

Samples for NMR were prepared by dissolving 15 mg of the biological material into 500  $\mu\text{L}$  of deuterium oxide and spectra were acquired on a Bruker *Avance III* 600 MHz spectrometer with TBI – probe at 25 °C.  $^1\text{H}$  NMR spectra were acquired as described in analysis section.

### Postsurgical wound treatment: 10% iodine solution and AgNP – based cream – *in vivo* assays

Postsurgical treatment of caseous lymphadenitis in infected animals was conducted with 29 animals, 9 sheep and 20 goats in a research coordinated by Federal University of Bahia. All animals presented clinical symptoms of the disease and the presence of the bacteria in the affected lymph nodes was confirmed by microbiological assays. The animals underwent a surgical procedure that started with the trichotomy of the skin above the enlarged lymph node and disinfection with 70% ethanol. An incision was made with a sterile blade and all the caseous material was removed and collected in sterile vials for further microbiological processing and bacterial identification. The surgical wound was then treated with a 10% iodine solution in 70% ethanol (three times per week, for 8–10 weeks) or with the AgNP-based cream, one time just after the surgical treatment, the wound was filled with a cream to cover all the

lesion. Veterinarians (Federal University of Bahia, UFBA, Salvador, BA, Brazil) monitored animals for 10 weeks after the treatment, and clinical parameters (body temperature, respiratory and cardiac frequency, hydration profile, colour of mucosa) were weekly taken and the size and profile of the wounds were recorded. This work was approved by the Committee on Ethics in Animal Experimentation of the Veterinary School of the Federal University of Bahia (number 35/2017).

### NMR analyses

Blood samples were collected weekly from 29 animals per 10 weeks. Overall, we used sheep (5/9) that underwent AgNP-based cream treatment and 4/9 that were treated with iodine. Goats (10/20) that underwent AgNP-based cream treatment and the other ten animals were treated with iodine. Serum samples were obtained by centrifugation and stored in a bio freezer at  $-80\text{ }^{\circ}\text{C}$  until the acquisition of NMR spectra. NMR analyses were done from serum prepared by dilution 1/1 (v/v), with 250  $\mu\text{L}$  of deuterium oxide ( $\text{D}_2\text{O}$  99.9%, Sigma Aldrich) using 5 mm NMR tubes.  $^1\text{H}$  NMR spectra were acquired using WATERGATE pulse sequence (p3919gp) with 128 scans, receptor gain (RG) of 101, FID size of 32 768 in a spectral width of 12.02 ppm. The  $\text{CH}_3$ - lactate signal (d, 3H,  $\delta$  1.33,  $^3J$  = 7.0 Hz) was used as a reference. The  $\text{T}_2$ -edited  $^1\text{H}$  NMR spectra were acquired using the cpmg1d (Carr-Purcell Meiboom-Gill) pulse sequence with 256 scans, receptor gain (RG) of 203, FID size of 65 536 in a spectral width of 20.55 ppm, 240 loops and processed with LB = 1.00 Hz. Two-dimensional spectra (HSQC) were acquired using the 600.17 MHz frequency domain spectrometer for F2 and 150.91 MHz in the F1 domain with a free induction decay size (FID) of 4096 (F2) and 256 (F1) data points and 16 “ghost” scans were used. HSQC spectra were acquired with an acquisition time of  $2.129 \times 10^{-1}$  s (F2) and  $4.437 \times 10^{-3}$  s (F1), using the hsqcetdgtppsp.3 pulse sequence. The spectra were processed using LB = 1.00 for F2 and LB = 0.30 for F1. NMR acquired spectra were divided into two groups: sheep (O) and goats (C) group.

Both groups were classified by type of the treatment – iodine (10%) (I) and AgNP-based cream (P), and all spectra were normalized by sum, with exclusion of residual water signal (HDO from  $\delta$  4.20 to 5.50) and exported as matrix for chemometrics analyses using software MetaboAnalyst 3.0.

The samples from the *C. pseudotuberculosis* extract were divided into three groups. The first group refers to extract, the second group represents the extract of post-ampicillin treated bacteria and the third group – the extract with AgNP from orange peel.

### Inductively coupled plasma optical emission spectroscopy

Presence of Ag(I) in animal serum samples was determined using Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES) technique, Perkin-Elmer – Optima 8300. An analytical curve, with silver(I) of ICP standard (Grupo Química, conc. 1000 mg  $\text{L}^{-1}$ , 1 g Ag(I) per 2 to 5%  $\text{HNO}_3$ ) was prepared



and the serum sample from sheep 564 P\_O, after application of AgNP-based cream was analysed.

## Results and discussion

### Minimum inhibitory concentration and scanning electron microscopy

The physical and chemical characterization of the nanoparticles used in this study can be found in previous articles.<sup>17,38</sup> Inspection of *C. pseudotuberculosis* growth was determined visually in the plate wells. The rows in which the turbidity could not be observed (characteristic for bacterial growth) were considered as AgNP concentrations that completely inhibited the microorganism growth. The MIC value obtained for *C. pseudotuberculosis* of *Fusarium oxysporum* nanosilver was  $33.5 \pm 2.0 \mu\text{g mL}^{-1}$ , and of orange peel nanosilver was  $22 \pm 2.0 \mu\text{g mL}^{-1}$ .<sup>22</sup> In addition, AgNPs were bacteriostatic at the same concentrations.

The SEM images of *C. pseudotuberculosis* versus biogenic silver nanoparticles are presented in Fig. S1 (ESI<sup>†</sup>). It can be observed that there are bacterial clusters (spheres and rods) at AgNP MIC when compared to the other conditions. The cells appear to be deformed in an environment with organic matter, which may indicate the presence of cell debris. Some clear spots have been observed, which may be attributed to the nanoparticles, much smaller than the cells of *C. pseudotuberculosis* ( $0.5\text{--}0.8 \mu\text{m}$  per  $1.0\text{--}3.0 \mu\text{m}$ ). The mechanism of antimicrobial action of silver nanoparticles is not completely known, however, there are some theories that explain the performance of silver(I) and silver(0) on bacteria.<sup>21,40–42</sup>

### Chemometrics on NMR data from test performed *in vitro* with *C. pseudotuberculosis* extracts

Fig. 1 shows the superposition of  $^1\text{H}$  NMR spectra obtained through *in vitro* tests with *C. pseudotuberculosis*, where AgNP effects were exposed in blue.

The PCA of  $^1\text{H}$  NMR data from *C. pseudotuberculosis* extracts are shown in Fig. S2 (ESI<sup>†</sup>). The score graph points to a significant separation between the three groups. Group 1 (extract) separates well from the groups 2 and 3, in PC 1. Groups 2 and 3

also show separation tendency but less pronounced, which is to be expected because they refer to the extracts treated with antimicrobials. The analysis of the loading graph (Fig. S2<sup>†</sup>) indicates that there are two regions responsible for the differentiation between the samples in PC 1. One of them varies from 0.91 to 0.94 ppm and is in the positive region in PC 1 and at the 1.45 ppm in negative PC 1 region. In PC 2 we also found the region of 1.45 ppm, but in this case, it showed positive loadings. Also, it was observed that chemical shift at 1.44 ppm showed negative loadings. The metabolites with chemical shift at 1.45 ppm were present in the highest concentration in the group 1, whereas the metabolites in the region between 0.91 and 0.94 ppm showed greater amounts in groups 2 and 3. It is important to note that these are relative concentrations because no quantitative experiments were performed. As PCA is only an exploratory analysis of the data, an analysis of PLS-DA was also performed.

The results of the PLS-DA model were similar to the PCA and there was also a significant separation between the groups, as can be observed in Fig. 2. Group 1 separates well from groups 2 and 3, in PC 1 (variance 29.8%), while groups 2 and 3 were separated from each other in PC 2 (variance 19.6%).

The analysis of the loading graph points to three important regions: (A) 0.91 and 0.94 ppm in PC 1 and (B) 1.44 and 1.45 ppm in PC 1; and (C) 1.44 to 1.45 ppm in PC 2. The chemical shifts around 0.90 ppm refer to the lipid region and at 1.44 ppm to aliphatic hydrogens from the carbon chains that belong to the mycolic acid, which is the main constituent of long chain lipids in cell wall of target mycobacteria.<sup>43–45</sup> The analysis of the VIP score graph (Fig. 3) confirms the conclusions obtained from the loading graph.

The importance of the variances with chemical shifts at 1.44 and 3.68 ppm can be attributed to mycolic acid long chains from the cell wall in *C. pseudotuberculosis* extracts. Inosine and adenosine are also present in higher concentrations in extract treated with AgNPs, due to defence of bacteria against silver nanoparticles and higher production of extracellular adenosine. Mature products of adenosine synthases, in Gram-positive bacteria are localized in the bacterial cell-wall envelope and are responsible for the increase of extracellular concentrations of the potent immunosuppressive molecule adenosine and, through this mechanism, can perturb immune defences and




Fig. 1  $^1\text{H}$  NMR data of *C. pseudotuberculosis* extract (red line, 1), after addition of ampicillin (green line, 2) and after addition of AgNPs (blue line, 3).




Fig. 2 Chemometrics on NMR data from tests with *C. pseudotuberculosis*: 2D scores plot of the PLS-DA analysis (left), with variance of 29.8% in PC 1 and 19.6% in PC 2, and the PLS-DA loadings graph (right). The red circles present the group of *C. pseudotuberculosis* extract, the green circles correspond to *C. pseudotuberculosis* extract after addition of ampicillin and blue circles represent the *C. pseudotuberculosis* after addition of AgNPs.








Fig. 3 Importance of the variables (VIP) obtained in PLS-DA model for the *C. pseudotuberculosis* extracts. The coloured boxes on the right indicate the relative concentrations of the corresponding metabolites in 1–3 groups. The numbers at the left side are chemical shifts of metabolites. The group 1 is *C. pseudotuberculosis* extract, group 2 correspond to *C. pseudotuberculosis* extract treated with the ampicillin and group 3 represents *C. pseudotuberculosis* extract after AgNP treatment.

promote their survival in host tissues.<sup>46</sup> AgNPs could induce cell death through increased membrane permeability and inactivation of the bacterial respiratory chain.<sup>47–49</sup>

The Fig. S3 (ESI<sup>†</sup>) represents the cross-validation of the PLS-DA model. The value of  $Q^2 > 0.4$  and the value of  $R^2$  (significantly high) point to a valid model.

### Biogenic AgNP-based cream – effects on wounds

A topical epidermal administration of water-in-oil cream emulsions or ointment as carriers of active substances enables their penetration to deeper layers of the animals' skin. Epidermal lipids are non-polar, composed from ceramides, sterol, fatty acids and lipophilic molecules and therefore, penetration through the stratum corneum is facilitated.<sup>50</sup> After removal of nodules caused by the bacteria *C. pseudotuberculosis*, the animals were treated with AgNP-based cream or iodine solution and monitored for a period of ten weeks, in which iodine procedure was repeated three times per week. It has been observed that wounds were healed just after two weeks (Fig. 4) when AgNP-based cream treatment was used, differently for seen for iodine solution application that took a two to three times longer treatment period. Most of all, AgNP-based cream treated animals did not presented alterations of body temperature, respiratory and cardiac rate, mucosa coloration, as well as, there were no signals of photo-sensibilization in the treated skin and wound.

The action of the AgNP cream prevents the further formation of colonies of *C. pseudotuberculosis* as seen in MIC assays. In general, shallow skin lesions heal efficiently within the time of 2 weeks, compromising the epidermal cicatrix at the site of the injury. Most of the wounds do not fully regenerate and leave a connective tissue scar on the surface. Many wounds involve damage to blood vessels and provide a temporary repair, which initiates with hemostasis.<sup>26</sup> In haemostasis, a fibrin clot temporarily plugs the damage site and, in subsequent days,



Fig. 4 Animals after chirurgical removal of nodules caused by the bacteria *C. pseudotuberculosis* (three sheep, first row). The same sheep are shown 2 weeks after application of AgNP-based cream (second row).

starts the healing process. There are five phases in wound healing: haemostasis, inflammation, cellular migration and proliferation, protein synthesis and wound contraction, and, lastly, remodelling. Because there is some overlap between these phases, they have been condensed into three phases: inflammation, proliferation, and remodelling.<sup>23,26</sup> There is a reservoir of cytokines and growth factors released by activated degranulating platelets after clotting. During the inflammatory phase, these chemicals signal process and sequential infiltration of inflammatory cells (neutrophils, macrophages, and lymphocytes) at the wound site.<sup>23,25,26,51</sup> Neutrophils accumulate within minutes at the injury site to engulf and clear up any contaminating bacteria. Later, macrophage cells phagocytose neutrophils and apoptotic cells and undergo phenotypic transition to the reparative state that stimulates keratinocytes, fibroblasts and angiogenesis. Later, macrophage cells phagocytose neutrophils and apoptotic cells and undergo phenotypic transition to the reparative state, which stimulates keratinocytes, fibroblasts and angiogenesis.<sup>52</sup> Herein, there are clear indications that silver incorporated into the oily base cream can promote wound healing, reduce the inflammatory phase and increase the proliferation time and re-modeling.<sup>23</sup>

It is very important to emphasize that the applied AgNP-based cream treatment had a positive effect on wound healing, which also has been shown in several papers. Recently, Stojkowska *et al.*<sup>53</sup> compared commercial treatment (Sulfadiazine cream 1%) with wet and dry alginate microfibers with AgNPs of the second-degree thermal wounds in Wistar rats. Histopathological analyses pointed to improved granulation and reepithelization, organized extracellular matrices in a treated group, and no harmful effects of silver.<sup>53</sup> Similar, positive effects were demonstrated in experiment by Tian *et al.*<sup>23</sup> where treated burn wounds of Wistar rats with nanosilver dressings were monitored through cytokines' profiles during the treatment. Improved wound healing, reduced appearance of scars, decrease in inflammation-indicating cytokines (IL-10, IL-6, TGF- $\beta$ 1, VEGF and IFN- $\gamma$ ), without any detrimental effect on the metabolism of the animals were reported.<sup>23</sup> Moreover, there are results of various wound dressings, gaze, gels, solutions and creams based on nanosilver, which improve wound healing, increase rate of proliferation of the fibroblasts, accelerate



epithelization and reveal a clean environment through the antimicrobial properties of silver(I) present.<sup>54</sup>

### Metabolomic NMR insights of goats and sheep serum samples

Metabolomics serum <sup>1</sup>H NMR analyses were applied for evaluation of effects of AgNP-based cream on serum metabolome. In Fig. 5, serum <sup>1</sup>H NMR spectra are presented, which correspond to the administration of iodine solution (10%) and AgNP-based cream.

After the exclusion of the HDO signal, for each analysed group (Fig. S4 and S5, ESI†) the mean spectra were obtained. After the subtractions, between the mean spectra of iodine and AgNP-based cream for both animals' groups (Fig. S6 and S7†), some small differences in blood metabolomes are seen. Therefore, according to the <sup>1</sup>H NMR data, the two treatments did not cause differences in most NMR metabolites signals, except in the lactate signal ( $\delta$  1.33) and sugar region ( $\delta$  3.00–4.00). Cited differences could be indicative for longer inflammation period in the area of the wound, which was observed during the treatment with iodine solution.

The scores in PC 1 and PC 2 showed variances of 28.2% in PC 1 and 14.8% in PC 2, and do not point to separation even after exclusion of two outliers (569\_1I C and C543\_8P) as illustrated in Fig. S8 (ESI†). Observing the loading graph (Fig. S8†) for PC 1 and PC 2, there are no significant differences between two treatments, except the ones observed in the lactate region, confirming observation made upon analysis of the <sup>1</sup>H NMR mean spectra. Fig. S9† (ESI†) shows the PC 1 vs. PC 2 scores, with 40.6% variance in PC 1 and 24.4% in PC 2 obtained for samples from sheep. No significant differences or trend in the separation of the samples were observed. The loadings point to lactate signal ( $\delta$  1.33) with negative value for PC 1 and positive for PC 2. Thus, prolonged inflammation in samples treated with 10% iodine solution and also the prolonged wound healing in iodine treated animals might have provoked these differences. In addition, the results of PLS-DA also did not point to a trend for separation of the groups, so it may be assumed that both treatment methods affected the metabolism of the animals in a very similar way when compared serum metabolites.




Fig. 5 <sup>1</sup>H NMR of serum samples taken from goats treated with iodine solution 10% (red line) and AgNP-based cream (blue line). The residual water signal (HDO of 4.20 to 5.50 ppm) is not shown.




Fig. 6 Serum NMR metabolomics obtained for goats: PLS-DA scores (left, two outliers were excluded – 569\_1I C and 543\_8P C), and the PLS-DA loading graph (right). The green circles present goats treated with the AgNP-based cream (P) and the red circles correspond to animals treated with iodine solution 10% (I).

The score plot of PLS-DA method (Fig. 6) confirms that serum samples from the goats are very similar and almost superimposed (two outliers, 569\_1I C and 543\_8P C were excluded before performing the PLS-DA analysis).

The total cross-validation test (LOOCV) for the PLS-DA model showed  $R^2$  inferior to 0.4 in the fifth component and  $Q^2$  lower than 0.05, which implies that the proposed model is valid. The distribution of the random class assignments according to the permutation test presented in the histogram for the proposed PLS-DA model showed significant results. The proposed model can be considered valid in 99% of cases since the observed statistic for 100 components is inferior to 0.01.

By proposing the PLS-DA model, it was shown that the most important variables belong to the signals of the metabolites shown in Fig. 7. Chemical shifts on  $\delta$  0.85 belong to the signal of low-density lipids,  $\delta$  1.25 to the decanoic acid (capric acid, found naturally in the milk of various mammals),  $\delta$  1.33 to the lactate signal (3H, d,  $^3J$  = 7 Hz),  $\delta$  2.04 to glutamate (H6, m),  $\delta$  2.73 to citrate (2H, d,  $^3J$  = 16 Hz), and finally  $\delta$  3.26 and 3.56 to the glucose multiple resonances. These substances showed relatively high concentration in the serum when animals were treated with the 10% iodine solution, probably as a consequence of prolonged inflammation and slower wound healing.<sup>55</sup>






Fig. 7 Serum NMR metabolites observed for goats: importance of variables (VIP Scores) identified by PLS-DA model. The coloured boxes on the right indicate the relative concentrations of the corresponding metabolite in each group. The numbers at the left side are chemical shifts of the corresponding metabolites. Goats treated with AgNP-based cream (P) and animals treated with 10% iodine solution (I).





**Fig. 8** Serum NMR metabolomics obtained for sheep: 3D score plot of the PLS-DA analysis (left), with excluded outliers, and the PLS-DA loading graph (right). The models were constructed from the matrix normalized by the sum and mean centred after the exclusion of outliers. The green circles present sheep treated with AgNP-based cream (P) and the red circles correspond to animals treated with 10% iodine solution (I).



**Fig. 9** Serum NMR metabolites found in sheep: importance of variables (VIP) identified by PLS-DA. The coloured boxes on the right indicate the relative concentrations of the corresponding metabolites in each studied group. Goats treated with AgNP-based cream (P) and animals treated with 10% iodine (I).

The plot graph using the PLS-DA method presented in Fig. 8, confirmed that there is no separation between NMR metabolome spectra from sheep.

The total cross-validation test (LOOCV) for the PLS-DA model showed  $R^2$  lower than 0.4 in the fifth component and  $Q^2$  lower than 0.05. The model is valid in 94% of the cases. The scores of 30 metabolites' signals (Fig. 9) related to the sheep samples point to the highest importance of lactate ( $\delta$  1.33 and 4.12), for both types of treatments, of fatty acids, decanoic acid ( $\delta$  1.25–1.26) after treatment with AgNP-based cream. Samples of sheep treated with iodine solution showed: norleucine ( $\delta$  3.73), phosphocholine ( $\delta$  3.27), citrate ( $\delta$  2.73), glutamate ( $\delta$  2.04), choline ( $\delta$  3.56) and low-density lipids ( $\delta$  0.85–0.86) as the most important VIP. Among these metabolites, decanoic acid was reported as volatile compound,<sup>56</sup> and norleucine or aminocaproic acid also compose sheep metabolome.

### Inductively coupled plasma-optical emission spectrometry ICP-OES

Concentration of Ag(I) in animal serum after the application of AgNP-based cream was determined. The highest concentration of Ag(I) was lower than 10 ppm ( $\mu\text{g L}^{-1}$ ). As seen in the

histogram of silver ion concentration obtained from sheep sample 564 treated with AgNP-based cream (Fig. S10, ESI<sup>†</sup>), only a slight variation of silver(I) was detected, but during treatment, the ion concentration did not exceed 10 ppm. Since the concentration of free ions in the course of treatment with commercial cream (Sulfadiazine cream 1%) exceeds, in some cases, much more than 10 ppm,<sup>57</sup> we can conclude that the treatment we proposed with AgNP-based cream accumulates smaller amount of free Ag(I) ions in blood of the treated animals.

## Conclusions

Cream with biogenic silver nanoparticles was prepared and used for wound treatment after surgical removal of nodules caused by caseous lymphadenitis disease in sheep and goats. With the aim to compare the proposed and conventional treatment with 10% iodine solution, serum metabolomics by NMR was done. All biochemical tests pointed to a significant clinical improvement of the AgNP-based cream treated animals without any metabolic or clinical change. These observations indicate that new treatment had no side effects on animals. In addition, the treatment with the AgNP-based cream accelerated up to 2- or 3-times wound healing. AgNP-based cream treatment improved animals' recovery from CL, as no recurrence of CL was noted in any of the treated animals.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

Authors would like to thank FAPESP, CAPES and CNPq for a scholarship (FAPESP No. 2015/12534-5), grants and financial supports (FAPESP No. 2018/06510-4 and 2014/18938-8). Also, the NMR facility at the Institute of Chemistry, University of Campinas, Campinas, SP, Brazil is kindly acknowledged.

## References

- W. M. Silva, F. A. Dorella, S. C. Soares, G. H. M. Souza, T. L. P. Castro, N. Seyffert, H. Figueiredo, A. Miyoshi, Y. L. Loir, A. Silva and V. Azevedo, A shift in the virulence potential of *Corynebacterium pseudotuberculosis* biovar *ovis* after passage in a murine host demonstrated through comparative proteomics, *BMC Microbiol.*, 2017, **17**, 55.
- D. J. Haas, E. M. S. Dorneles, S. J. Spier, S. P. Carroll, J. Edman, V. A. Azevedo, M. B. Heinemann and A. P. Lage, Infection, genetics and evolution molecular epidemiology of *Corynebacterium pseudotuberculosis* isolated from horses in California, *Infect., Genet. Evol.*, 2017, **49**, 186–194.
- W. M. Silva, E. L. Folador, S. C. Soares, G. H. M. F. Souza, A. V. Santos, C. S. Sousa, H. Figueiredo, A. Miyoshi, Y. L. Loir, A. Silva and A. Vasco, Label-free quantitative proteomics of *Corynebacterium pseudotuberculosis* isolates





- reveals differences between Biovars ovis and equi strains, *BMC Genomics*, 2017, **18**, 451.
- 4 M. W. Paton, I. R. Rose, R. A. Hart, S. S. Sutherland, A. R. Mercy, T. M. Ellis and J. A. Dhaliwal, New infection with *Corynebacterium pseudotuberculosis* reduces wool production, *Aust. Vet. J.*, 1994, **71**, 47–49.
  - 5 S. Almeida, S. Tiwari, D. Mariano, F. Souza, S. B. Jamal, N. Coimbra, R. T. Raittz, F. A. Dorella, A. F. Carvalho, F. L. Pereira, S. C. Soares, C. A. G. Leal, D. Barh, P. Ghosh, H. Figueiredo, L. F. Moura-Costa, R. W. Portela, R. Meyer, A. Silva and V. Azevedo, The genome anatomy of *Corynebacterium pseudotuberculosis* VD57 a highly virulent strain causing Caseous lymphadenitis, *Stand. Genomic Sci.*, 2016, **11**, 29.
  - 6 J. G. M. Pontes, F. B. Santana, R. W. Portela, V. Azevedo, R. J. Poppi and L. Tasic, Biomarkers of the Caseous Lymphadenitis in sheep by NMR-based metabolomics, *Metabolomics*, 2017, **7**, 190.
  - 7 D. M. Rhodes, K. G. Magdesian, B. A. Byrne, P. H. Kass, J. Edman and S. J. Spier, Minimum Inhibitory Concentrations of equine *Corynebacterium pseudotuberculosis* isolates (1996–2012), *J. Vet. Intern. Med.*, 2015, **29**, 327–332.
  - 8 D. Abebe and T. S. Tessema, Determination of *Corynebacterium pseudotuberculosis* prevalence and antimicrobial susceptibility pattern of isolates from lymph nodes of sheep and goats at an organic export abattoir, Modjo, Ethiopia, *Lett. Appl. Microbiol.*, 2015, **61**, 469–476.
  - 9 F. Bassyouni, N. Elhalwany, M. A. Rehim and M. Neyfeh, Advances and new technologies applied in controlled drug delivery system, *Res. Chem. Intermed.*, 2015, **41**, 2165–2200.
  - 10 J. L. Clement and P. S. Jarrett, Antibacterial silver, *Met.-Based Drugs*, 1994, **1**, 467–482.
  - 11 M. M. Mohamed, S. A. Fouad, H. A. Elshoky, G. M. Mohammed and T. A. Salaheldin, Antibacterial effect of gold nanoparticles against *Corynebacterium pseudotuberculosis*, *Int. J. Vet. Sci. Med.*, 2017, **5**, 23–29.
  - 12 M. da C. A. Sá, J. L. A. Veschi, G. B. Santos, E. S. Amanso, S. A. S. Oliveira, R. A. Mota, G. Veneroni-Gouveia and M. M. Costa, Activity of disinfectants and biofilm production of *Corynebacterium pseudotuberculosis*, *Pesqui. Vet. Bras.*, 2013, **33**(11), 1319–1324.
  - 13 I. Chopra, The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern?, *J. Antimicrob. Chemother.*, 2007, **59**, 587–590.
  - 14 M. Yamanaka, K. Hara and J. Kudo, Bactericidal actions of a silver ion solution on *Escherichia coli*, studied by energy-filtering transmission electron microscopy and proteomic analysis, *Appl. Environ. Microbiol.*, 2005, **71**, 7589–7593.
  - 15 M. Vogler, D. Dinsdale, M. J. S. Dyer and G. M. Cohen, Bcl-2 inhibitors: small molecules with a big impact on cancer therapy, *Cell Death Differ.*, 2009, **16**, 360–367.
  - 16 W. K. Jung, H. C. Koo, K. W. Kim, S. Shin, S. H. Kim and Y. H. Park, Antibacterial activity and mechanism of action of the silver ion in *Staphylococcus aureus* and *Escherichia coli*, *Appl. Environ. Microbiol.*, 2008, **74**, 2171–2178.
  - 17 D. Ballottin, S. Fulaz, F. Cabrini, J. Tsukamoto, N. Durán, O. L. Alves and L. Tasic, Antimicrobial textiles: Biogenic silver nanoparticles against *Candida* and *Xanthomonas*, *Mater. Sci. Eng., C*, 2017, **75**, 582–589.
  - 18 V. L. Praba, M. Kathirvel, K. Vallayachari, K. Suren-dar, M. Muthuraj, P. J. Jesuraj, S. Govindarajan and K. V. Raman, Bactericidal effect of silver nanoparticles against *Mycobacterium tuberculosis*, *J. Bionanosci.*, 2013, **7**, 282–287.
  - 19 R. Salomoni, P. Léo, A. F. Montemor, B. G. Rinaldi and M. / F. A. Rodrigues, Antibacterial effect of silver nanoparticles in *Pseudomonas aeruginosa*, *Nanotechnol., Sci. Appl.*, 2017, **10**, 115–121.
  - 20 N. Durán, G. Nakazato and A. B. Seabra, Antimicrobial activity of biogenic silver nanoparticles, and silver chloride nanoparticles: an overview and comments, *Appl. Microbiol. Biotechnol.*, 2016, **100**, 6555–6570.
  - 21 N. Durán, M. Durán, M. B. Jesus, A. B. Seabra, W. J. Fávaro and G. Nakazato, Silver nanoparticles: A new view on mechanistic aspects on antimicrobial activity, *Nanomedicine*, 2016, **12**, 789–799.
  - 22 L. Tasic, R. W. D. Portela, C. H. N. Barros, J. G. M. Pontes, D. Stanisic, and N. Durán, Formulação Farmacêutica e seu uso, Patente de Invenção, BR 10 2017 014836 0, 2017.
  - 23 J. Tian, K. K. Y. Wong, C. Ho, C. N. Lok, W. Y. Yu, C. M. Che, J. F. Chiu and P. K. Tam, Topical delivery of silver nanoparticles promotes wound healing, *ChemMedChem*, 2007, **2**, 129–136.
  - 24 J. E. Barrett, *Handbook of Experimental Pharmacology*, Springer Nature, 1978, vol. 49, ISSN: 0171-2004.
  - 25 C. Rigo, L. Ferroni, I. Tocco, M. Roman, I. Munivra-na, . Gardin, W. R. L. Cairns, V. Vindigni, B. Azzena, C. Barbante and B. Zavan, Active silver nanoparticles for wound healing, *Int. J. Mol. Sci.*, 2013, **14**, 4817–4840.
  - 26 M. B. Dreifke, A. A. Jayasuriya and A. C. Jayasuriya, Current wound healing procedures and potential care, *Mater. Sci. Eng., C*, 2015, **48**, 651–662.
  - 27 J. Jain, S. Arora, J. M. Rajwade, P. Omray, S. Khandelwal and K. M. Paknikar, Silver nanoparticles in therapeutics: Development of an antimicrobial gel formulation for topical use, *Mol. Pharm.*, 2009, **6**, 1388–1401.
  - 28 S. Halouska, B. Zhang, R. Gaupp, S. Lei, E. Snell, R. J. Fenton, R. G. Barletta, G. A. Somerville and R. Powers, Revisiting protocols for the NMR analysis of bacterial metabolomes, *Journal of Integrated OMICS*, 2013, **3**, 120–137.
  - 29 A. C. Dona, M. Kyriakides, F. Scott, E. A. Shephard, D. Varshavi, K. Veselkov and J. R. Everett, A guide to the identification of metabolites in NMR-based metabolomics/metabolomics experiments, *Comput. Struct. Biotechnol. J.*, 2016, **14**, 135–153.
  - 30 M. M. W. B. Hendriks, F. A. van Eeuwijk, R. H. Jellema, J. A. Westerhuis, T. H. Reijmers, H. C. J. Hoefslot and A. K. Smilde, Data-processing strategies for metabolomics studies, *Trends Anal. Chem.*, 2011, **30**, 1685–1698.
  - 31 J. G. M. Pontes, A. J. M. Brasil, G. C. F. Cruz, R. N. Souza and L. Tasic, NMR-based metabolomics strategies: plants, animals and humans, *Anal. Methods*, 2017, **9**, 1078–1096.





- 32 R. Bro and A. K. Smilde, Principal component analysis, *Anal. Methods*, 2014, **6**, 2812–2831.
- 33 J. Xia and D. S. Wishart, Metabolomic data processing, analysis, and interpretation using MetaboAnalyst, *Curr. Protoc. Bioinf.*, 2011, **034**, 14.10.1–14.10.48.
- 34 J. Xia and D. S. Wishart, Using MetaboAnalyst 3.0 for comprehensive metabolomics data analysis, *Curr. Protoc. Bioinf.*, 2016, **55**, 14.10.1–14.10.91.
- 35 A. Erban, B. De and C. Wagner, *US Pat.*, 10054066, 2013, vol. 2, 12.
- 36 P. S. Gromski, H. Muhamadali, D. I. Ellis, Y. Xu, E. Correa, M. L. Turner and R. Goodacre, A tutorial review: Metabolomics and partial least squares-discriminant analysis – a marriage of convenience or a shotgun wedding, *Anal. Chim. Acta*, 2015, **879**, 10–23.
- 37 E. Szymanska, E. Saccenti, A. K. Smilde and J. A. Westerhuis, Double-check: validation of di-agnostic statistics for PLS-DA models in metabolomics studies, *Metabolomics*, 2012, **8**, 3–16.
- 38 C. H. N. Barros, G. C. F. Cruz, W. Mayrink and L. Tasic, Bio-based synthesis of silver nanoparticles from orange waste: effects of distinct biomolecule coatings on size, morphology, and antimicrobial activity, *Nanotechnol., Sci. Appl.*, 2018, **11**, 1–14.
- 39 L. B. Santiago, R. R. Pinheiro, A. S. Rodrigues, L. Chapaval, I. F. Brito and F. G. C. Sousa, Avaliação *in vitro* da sensibilidade da *Corynebacterium pseudotuberculosis* frente a diferentes tipos de antissépticos e desinfetantes e determinação de sua curva de crescimento, *Arq. Inst. Biol.*, 2010, **77**, 593–600.
- 40 N. Durán, P. D. Marcato, R. De Conti, O. L. Alves, F. T. M. Costa and M. Brocchi, Potential use of silver nanoparticles on pathogenic bacteria, their toxicity and possible mechanisms of action, *J. Braz. Chem. Soc.*, 2010, **21**, 949–959.
- 41 K. K. Y. Wong and X. Liu, Silver nanoparticles — the real “silver bullet” in clinical medicine?, *MedChemComm*, 2010, **1**, 125–131.
- 42 C. Marambio-Jones and E. M. V. Hoek, A review of the antibacterial effects of silver nanomaterials and potential implications for human health and the environment, *J. Nanopart. Res.*, 2010, **12**, 1531–1551.
- 43 C. Brambilla, A. Sánchez-Chardi, M. Pérez-Trujillo, E. Julián and M. Luquin, Cyclopropanation of  $\alpha$ -mycolic acids is not required for cording in *Mycobacterium brumae* and *Mycobacterium fallax*, *Microbiology*, 2012, **158**, 1615–1621.
- 44 H. Marrakchi, M. A. Lanéelle and M. Daffé, *Review mycolic acids: Structures, biosynthesis, and beyond*, Cell Press, 2014, vol. 21, pp. 67–85.
- 45 J. C. Ruiz, V. D'Afonseca, A. Silva, A. Ali, A. C. Pinto, A. R. Santos, *et al.*, Evidence for reductive genome evolution and lateral acquisition of virulence functions in two *Corynebacterium pseudotuberculosis* strains, *PLoS One*, 2011, **6**, e18551.
- 46 V. Thammavongsa, J. W. Kern, D. M. Missiakas and O. Schneewind, Staphylococcus aureus synthesizes adenosine to escape host immune responses, *J. Exp. Med.*, 2009, **206**, 2417–2427.
- 47 Y. Yuan, Q. Peng and S. Gurunathan, Effects of silver nanoparticles on multiple drug-resistant strains of Staphylococcus aureus and Pseudomonas aeruginosa from mastitis-infected goats: An alternative approach for antimicrobial therapy, *Int. J. Mol. Sci.*, 2017, **18**, 569.
- 48 I. Sondi and B. Salopek-Sondi, Silver nano-particles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria, *J. Colloid Interface Sci.*, 2004, **275**, 177–182.
- 49 N. Beyth, I. Yudovin-Farber, M. Perez-Davidi, A. J. Domb and E. I. Weiss, Polyethyleneimine nanoparticles incorporated into resin composite cause cell death and trigger biofilm stress *in vivo*, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 22038–22043.
- 50 B. S. Series. Edition S., *Dry Skin and Moisturizers*, 2006.
- 51 J. Cabral, A. E. Ryan, M. D. Griffin and T. Ritter, Extracellular vesicles as modulators of wound healing, *Adv. Drug Delivery Rev.*, 2018, **129**, 394–406.
- 52 M. D. Leonida and I. Kumar, *Bionanomaterials for skin regeneration*, Springer International Publishing, 1st edn, 2016, p. 144.
- 53 J. Stojkowska, Z. D. I. Jancic, B. Bufan, M. M. R. Jankovic, V. Miskovic-Stankovic and B. Obradovic, Comparative *in vivo* evaluation of novel formulations based on alginate and silver nanoparticles for wound treatments, *J. Biomater. Appl.*, 2018, **32**(9), 1197–1211.
- 54 M. M. P. Silva, M. I. F. de Aguiar, A. B. Rodrigues, M. C. Miranda, M. A. M. Araújo, I. L. T. P. Rolim and A. A. A. Souza, The use of nanoparticles in wound treatment: a systematic review, *Rev. Esc. Enferm. USP*, 2017, **51**, e03272.
- 55 R. Haas, J. Smith, V. Rocherros, S. Nadkarni, T. Montero-Melendez, F. D'Acquisto, E. J. Bland, M. Bombardieri, C. Pitzalis, M. Perretti, F. M. Marelli-Berg and C. Mauro, Lactate regulates metabolic and pro-inflammatory circuits in control of T cell migration and effector functions, *PLoS Biol.*, 2015, **13**, e1002202.
- 56 V. T. de Souza, É. P. D. de Franco, M. E. de Araújo, M. C. Messias, F. B. Priviero, A. C. Frankland Sawaya and P. Oliveira Carvalho, Characterization of the antioxidant activity of aglycone and glycosylated derivatives of hesperetin: an *in vitro* and *in vivo* study, *J. Mol. Recognit.*, 2015, **29**, 80–87.
- 57 G. M. Davolli, K. N. Beavers, V. Medina, J. L. Sones, C. R. F. Pinto, D. L. Paccamonti and R. C. Causey, Concentrations of Sulfadiazine and Trimethoprim in Blood and Endometrium of Mares After Administration of an Oral Suspension, *J. Equine Vet. Sci.*, 2018, **1e4**.

